• Recruiting

NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant

NCT05354557: Phase 2 - Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)


iberdomide maintenance mskcc

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT05354557

Official Title: Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients With Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation or After Salvage Autologous Hematopoietic Cell Transplantation

First Posted : April 29, 2022


Click here to see details on ClinicalTrials.gov

 

CC-220 - Iberdomide

 

Drug: Iberdomide

 

Locations

United States, New Jersey

United States, New York

Posts Archive